CN
106-92-3
应用筛选条件
关键词:'106-92-3'
显示 1-30 共 190 条结果 关于 "106-92-3" 范围 技术文档
The Effective Use of Protein Kinase Inhibitors
104 96 98 89
PKA 2 91 35 17 94 95 105 106 96 66 97 91 104 104 96 96 70 99 87
PKCα 79 98 86 95 95 92 99 93 89 92 100 91 70
The Effective Use of Protein Kinase Inhibitors
104 96 98 89
PKA 2 91 35 17 94 95 105 106 96 66 97 91 104 104 96 96 70 99 87
PKCα 79 98 86 95 95 92 99 93 89 92 100 91 70
Data Sheet - SAB4200870
2420-28 (2010).
6. Zhang H., et al., Proc Natl Acad Sci USA.,
106: 2365-70 (2009).
7. Santacruz A., et al., Br J Nutr., 104:
83–92 (2010).
8. Wang L., et al., Appl Environ Microbiol.
Product Information Sheet-tripure-ro
custom fill 10 899 232 103
Sodium Dodecyl Sulfate (SDS) 1 kg 11 667 289 001
1 2 3
1 2 3
04
21
.0
50
40
92
20
01
9
https://www.sigmaaldrich.com
Verfication summary-03-0202-00
19.82 0.6 3% 158.53 4.6 3% 116%
3 1:16 9.33 0.6 6% 149.30 9.2 6% 110%
BRH1451740
3 MRD (1:2) 54.72 1.5 3% 109.45 3.0 3% -
3 1:4 29.09 0.4 1% 116.37 1.4 1% 106%
Verfication summary-03-0202-00
19.82 0.6 3% 158.53 4.6 3% 116%
3 1:16 9.33 0.6 6% 149.30 9.2 6% 110%
BRH1451740
3 MRD (1:2) 54.72 1.5 3% 109.45 3.0 3% -
3 1:4 29.09 0.4 1% 116.37 1.4 1% 106%
QC Range Sheet MCKP1-110K
LAG-3 Control 1 3240 – 6729 pg/mL CD27 Control1 464 - 964 pg/ml
Control 2 13982 - 29039 pg/mL Control 2 1939 - 4027 pg/ml
Data Sheet - S4183
Monoclonal Anti-Phospho-STAT3 reacts specifically
with human tyrosine-705 phosphorylated STAT3 protein
(92 kDa). It also reacts with mouse phospho-STAT3.
Monoclonal Anti-Phospho-STAT3 may be used for
detection
Validation and Qualification for Durapore® Sterilizing-Grade (0.22 µm) Membrane VMF4
16 16.0 >8.29 98
41 12.8 6.50 104 17 15.9 >8.29 98
52 12.6 6.50 108 18 15.6 >8.29 92
23 12.6 6.53 106 28 14.1 >8.36 85
4 12.4 6.59 108 29 14.0
CDK1/CyclinA2 active (C0244)
Lot Number 019K1567:
>85% (densitometry)
Figure 2.
Specific Activity of Lot Number 019K1567:
92 nmole/min/mg
0
100000
200000
300000
400000
500000
0 40 80 120 160
protein (ng)
Data Sheet - E2030
developed in rabbit using as
immunogen a synthetic peptide corresponding to amino
acid residues 92-106 of human EndoGlyx-1 conjugated
to maleimide-activated KLH. The antibody is affinity-
purified using
Data Sheet - J4127
Blood, 91, 4084-
4091 (1998).
3. Jones, P., et al., Stromal expression of Jagged-1
promotes colony formation by fetal hematopoietic
progenitor cells, Blood, 92, 1505-1511 (1998).
4. Walker, L
Quality Control Ranges: MILLIPLEX® MAP Human Cytokine/ Chemokine Magnetic Bead Panel
Control 2 447 – 928 pg/mL Control 2 497 – 1032 pg/mL
Flt-3L Control 1 106 – 221 pg/mL IL-3 Control 1 97
Microsoft Word - VP001 tech bulletin final
cultured for batch growth in
Mobius 3 L and 50 L Single-Use Bioreactors. While cells were seeded in the
50 L bioreactor at 1 106 viable cells/mL (vc/mL) and in the 3 L bioreactor at
5 105 vc/mL
High throughput sample preparation for the quantitation of drug compounds in serum samples
11% 97±3% 96±3% 81±6%
Taxol 92±3% 92±2% 96±10% 91±2% 90±2% 99±9%
Testosterone 106±3% 93±2% 104±11 102±2% 90±2% 88±8%
Verapamil 90±3% 96±2% 99±14% 91±2% 95±2% 102±11%
Warfarin 92±3% 92±3% 91±8% 90
RABBIT ANTI-Tau phosphoSerine 262 POLYCLONAL ANTIBODY
and GSK-3beta. FEBS Lett. 530(1-3):209-214.
Liu, F., et al. (2002) Role of glycosylation in hyperphosphorylation of tau in Alzheimer's
disease. FEBS Lett. 512:101-106.
Important Note: During
Product Information Sheet - MAK528
(U/mL)
1 100 μL + 0 μL 3.0
2 80 μL + 20 μL 2.4
3 60 μL + 40 μL 1.8
4 40 μL + 60 μL 1.2
5
Data Sheet - SAB4200683
References
1. Reimer, C., et al., Hybridoma, 3, 263-75 (1984).
2. Jefferis R., et al., Immunol Lett., 10, 223-52
(1985).
3. Walker AM., et al., PNAS USA, 92, 3278-82
(1995).
4. Hamilton RG., Clin
MOUSE ANTI-HUMAN BCL-XL
Natl. Acad. Sci. USA 91: 7350.
11. Gonzalez-Garcia, M. et al. (1995). Proc. Natl. Acad. Sci. USA 92: 4304.
12. Dole, M.G. et al. (1995). Can. Research 55: 2576.
13.
Data Sheet - L6287
discrasias", Prozanski,
W., and Keystone, E.C., Eds. Churchill Livingston,
Edinburgh- New York, pp 54-92, (1986).
lpg 9/99
Sigma brand products are sold through Sigma-Aldrich, Inc.
Sigma-Aldrich
Product Information Sheet - VP002
for batch
growth in Mobius® 3 L single-use bioreactors. Cells were seeded in the 3 L bioreactor at
6 × 105 viable cells (vc) per mL. Peak viable cell density (VCD) of 12 × 106 vc/mL was obtained
with viability
FlowCellect™ Annexin Red Kit (100 Tests)
STS
11%85%
2%2% 4%
36%60%
7%
92%5%
Uninduced 0.1uM STS 3uM STS
11%85%
2%2% 4%
36%60%
7%
92%5%
Anti-Cdk8 antibody produced in rabbit (C0238)
dependent kinase 8, a putative protein kinase
partner for cyclin C. Proc. Nat. Acad. Sci. USA, 92,
8871-8875 (1995).
2. Demetrick, D. J., et al., Chromosomal mapping of
the genes for the human
Data Sheet - K2011
et al, J. Immunoassay, 9, 275-296
(1988).
Product Information
3. Black, C.M., et al, J. Immunol. Meth., 106, 71-81
(1988).
4. Whicher, J.T., et al, Ann. Clin. Biochem., 24,
119-132 (1987
Bulletin - CHROP
abundant TF qPCR 0.5 - 2 x 106
Microarray 104 - 106
Sequencing 105 – 107
Medium abundance TF, e.g., RNAP II qPCR 2-10 x 106
Microarray 105 – 106
Sequencing 106 – 107
Product Information Sheet - MAK395
Assay
Buffer
Chromophore
(nmol/well)
1 0 L 100 L 0
2 2 L 98 L 2
3 4 L 96 L 4
4 6 L 94 L 6
5 8 L 92 L 8
6 10
Product Information Sheet - S4760
subclinical zinc deficiency in weaned piglets".
Technische Universität München, Dr. agr.
dissertation, p. 92 (2018).
14. Bryan, Dervan Dale Shian Lasien,
"Characterization of protein sources and their
Data Sheet - E4150
polycarbonate filter
(5 micron pore size) and 2 x 106 cells/ well (CCR-3
transfected Y3 rat myeloid cells) are added to the top
chamber. After incubation for 3 hours at 37 °C in a 5 %
CO2 humidified incubator
Application Note - RealTime ready Assays for Gene Expression Analysis in Biomarker Research and Early Drug Development
ready NF-kB
panel:
Testing of NF-kB panel of
92 targets with 52 cell line
samples
~100
Biomarker Discovery
Microarray data
& literature:
Selection of 92 targets
from the NF-kB pathway
~10000
Product Information Sheet - D0627
3. Henion, W.F. et al., Biochem. Biophys. Acta,
148(1), 106-113 (1967).
4. Swislocki, N.I., Anal. Biochem., 38(1), 260-269
(1970).
5. Schwede, F. et al., Pharmacol. Ther., 87(2-3)
1/7